摘要Denosumab is a monoclonal anti-RANKL antibody that inhibits bone resorption,increases bone mass,and reduces fracture risk.Denosumab discontinuation causes an extensive wave of rebound resorption,but the cellular mechanisms remain poorly characterized.We utilized in situ hybridization(ISH)as a direct approach to identify the cells that activate osteoclastogenesis through the RANKL/OPG pathway.ISH was performed across species,skeletal sites,and following recombinant OPG(OPG:Fc)and parathyroid hormone 1-34(PTH)treatment of mice.OPG:Fc treatment in mice induced an increased expression of RANKL mRNA mainly in trabecular,but not endocortical bone surface cells.Additionally,a decreased expression of OPG mRNA was detected in bone surface cells and osteocytes of both compartments.A similar but more pronounced effect on RANKL and OPG expression was seen one hour after PTH treatment.These findings suggest that bone surface cells and osteocytes conjointly regulate the activation of osteoclastogenesis,and that OPG:Fc treatment induces a local accumulation of osteoclastogenic activation sites,ready to recruit and activate osteoclasts upon treatment discontinuation.Analysis of publicly available single-cell RNA sequencing(scRNAseq)data from murine bone marrow stromal cells revealed that Tnfsf11+cells expressed high levels of Mmp13,Limch1,and Wif1,confirming their osteoprogenitor status.ISH confirmed co-expression of Mmp13 and Tnfsf11 in bone surface cells of both vehicle-and OPG:Fc-treated mice.Under physiological conditions of human/mouse bone,RANKL is expressed mainly by osteoprogenitors proximate to the osteoclasts,while OPG is expressed mainly by osteocytes and bone-forming osteoblasts.